文献リスト

1）Gershon AS, Warner L, Cascagnette P, et al. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011; 378: 991-6

2）日本呼吸器学会COPDガイドライン第3版作成委員会．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン．東京：メディカルレビュー社；2009

3）Agusti A, Calverley PM, Celli B, et al. Characteri­sation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122

4）Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstruc­tive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003; 167: 544-9

5）Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than air­way obstruction in patients with COPD. Chest. 2002; 121: 1434-40

6）McGarvey LP, John M, Anderson JA, et al. Ascer­tain­ment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007; 62: 411-5

7）小賀　徹．COPDと肺線維症における慢性炎症．実験医．2011; 29（増刊）: 1572-9

8）Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12

9）Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, mana­ge­ment, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com（updated 2011）

10）Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011; 365: 1184-92

11）Casanova C, de Torres JP, Aguirre-Jaime A, et al. The progression of chronic obstructive pulmo­nary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011; 184: 1015-21

12）Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185: 44-52

13）Oga T, Tsukino M, Hajiro T, et al. Multi­dimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmo­nary disease. Allergol Int. 2010; 59: 257-65

14）Celli BR, Cote CG, Lareau SC, et al. Predictors of survival in COPD: more than just the FEV1. Respir Med. 2008; 102（Suppl 1）: S27-35

15）Jones PW, Harding G, Berry P, et al. Develop­ment and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34: 648-54

16）宮本顕二．MRC息切れスケールをめぐる混乱．日呼吸会誌．2008; 46: 593-9

17）Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD Assessment Test（CAT） in a cross-sectional European study. Eur Respir J. 2011; 38: 29-35

18）小賀　徹．COPDにおけるHRQOL測定の意義．呼と循．2006; 54: 1083-9

19）Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with COPD. Am J Respir Crit Care Med. 2012; 186: 155-61

20）Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2009; 77: 305-13

21）Ferrazza AM, Martolini D, Valli G, et al. Cardiopulmonary exercise testing in the func­tional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009; 77: 3-17

22）Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009; 374: 704-11

23）Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009; 180: 1189-95

24）Sin DD, Pahlavan PS, Man SF. Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis. 2008; 2: 65-74

25）Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010; 65: 930-6

26）Celli BR, Locantore N, Yates J, et al. Inflam­matory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185: 1065-72

27）Oga T, Nishimura K, Tsukino M, et al. Longitudi­nal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007; 101: 146-53

28）Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7: 95-9

29）Glaab T, Vogelmeier C, Buhl R. Outcome mea­sures in chronic obstructive pulmonary disease（COPD）: strengths and limitations. Respir Res. 2010; 11: 79

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp